Transcription factor networks as targets for therapeutic intervention of cancer: The breast cancer paradigm

Molecular Medicine

Volumn 17, Issue 11, 2011, Pages 1133-1136

  Karamouzis, Michalis V ^a   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; FULVESTRANT; I KAPPA B KINASE INHIBITOR; PACLITAXEL; PEPTIDE DERIVATIVE; PROTEASOME INHIBITOR; STAT3 PROTEIN; STAT5 PROTEIN; TAMOXIFEN; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1;

BREAST CANCER; BREAST CARCINOMA; BREAST TUMOR; CANCER CELL; CANCER RESISTANCE; CANCER THERAPY; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING;

BREAST NEOPLASMS; FEMALE; GENE REGULATORY NETWORKS; HUMANS; MOLECULAR TARGETED THERAPY; TRANSCRIPTION FACTORS;

EID: 82855177919     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00315     Document Type: Note

References (40)

1. Singh S, Johnson J, Chellappan S. (2010) Small molecule regulators of Rb-E2F pathway as modulators of transcription. Biochim. Biophys. Acta. 1799:788-94.
2. Ozcan S, Andrali SS, Cantrell JEL. (2010) Modulation of transcription factor function by O-Glc-NAc modification. Biochim. Biophys. Acta. 1799:353-64.
3. Battaglia S, Maguire O, Campbell MJ. (2010) Transcription factor co-repressors in cancer biology: roles and targeting. Int. J. Cancer. 126:2511-9.
4. Pan Y, Tsai CJ, Ma B, Nussinov R. (2010) Mechanisms of transcription factor selectivity. Trends Genet. 26:75-83.
5. Huang B, Yang XD, Lamb A, Chen LF. (2010) Posttranslational modifications of NF-kappaB: another layer of regulation for NF-kappaB signaling pathway. Cell Signal. 22:1282-90.
6. Rodriguez-Martinez JA, Peterson-Kaufman KJ, Ansari AZ. (2010) Small-molecule regulators that mimic transcription factors. Biochim. Biophys. Acta. 1799:768-74.
7. MacQuarrie KL, Fong AP, Morse RH, Tapscott SJ. (2011) Genome-wide transcription factor binding: beyond direct target regulation. Trends Genet. 27:141-8.
8. Nilsson S, Gustafsson JA. (2011) Estrogen receptors: therapies targeted to receptor subtypes. Clin. Pharmacol. Ther. 89:44-55.
9. Ahmad N, Kumar R. (2011) Steroid hormone receptors in cancer development: a target for cancer therapeutics. Cancer Lett. 300:1-9.
10. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. (2009) Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol. 10:709-17.
11. Louie MC, McClellan A, Siewit C, Kawabata L. (2010) Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance. Mol. Cancer Res. 8:343-52.
12. Zhang Y, et al. (2011) Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res. 13:R52.
13. Probst-Hensch NM, et al. (2010) IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity. Clin. Cancer Res. 16:1025-32.
14. Carboni JM, et al. (2009) BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol. Cancer Ther. 8:3341-9.
15. Chakraborty AK, Welsh A, Digiovanna MP. (2010) Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and proapoptotic effects of anti-estrogens in human breast cancer cell lines. Breast Cancer Res. Treat. 120:327-35.
16. Aguilera C, et al. (2011) C-Jun N-terminal phosphorylation antagonizes recruitment of the Mbd3/NuRD repressor complex. Nature. 469:231-5.
17. Zhang X, et al. (2011) Genome-wide analysis reveals PADI4 cooperates with Elk-1 to activate c-Fos expression in breast cancer cells. PLoS Genet. 7:1-15.
18. Wortham NC, et al. (2009) The DAED box protein p72 regulates ERα-/estrogen-dependent transcription and cell growth, and is associated with improved survival in ERα positive breast cancer. Oncogene. 28:4053-64.
19. Petrocca F, Lieberman J. (2011) Promise and challenge of RNA interference-based therapy for cancer. J. Clin. Oncol. 29:747-54.
20. Eades G, et al. (2011) MiR-200a regulates SIRT1 and EMT-like transformation in mammary epithelial cells. J. Biol. Chem. 286:25992-6002.
21. O'Day E, Lal A. (2010) MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 12:201.
22. Adams BD, Cowee DM, White BA. (2009) The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-α (ERα) signaling and a luminal phenotype in MCF-7 breast cancer cells. Mol. Endocrinol. 23:1215-30.
23. Somlo G, et al. (2011) Correlation between miRNA and gene expression profiles and response to neoadjuvant chemotherapy in patients with locally advanced and inflammatory breast cancer. J. Clin. Oncol. 29 Suppl:A548.
24. Lai D, Ho KC, Hao Y, Yang X. (2011) Taxol resistance in breast cancer cells is mediated by the Hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 71:2728-38.
25. Wu Y, Zhou BP. (2010) TNF-alpha/NF-kappaB/ Snail pathway in cancer cell migration and invasion. Br. J. Cancer. 102:639-44.
26. Hisamatsu Y, et al. (2011) The expression of GATA-3 and FOXA1 in breast cancer: the biomarkers of hormone sensitivity in luminal-type tumors. J. Clin. Oncol. 29 Suppl:A599.
27. McCune K, et al. (2010) Prognosis of hormonedependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet. Cancer Res. 70:685-96.
28. Ring A, Evgrafov O, Knwoles J, Kahn M. (2011) Targeting _-catenin/CBP interaction in breast cancer. J. Clin. Oncol. 29 Suppl:A10516.
29. Kim E, et al. (2011) Biomarkers affecting metastasis and survival in paired tissues of 107 patients with metastatic breast cancer. J. Clin. Oncol. 29 Suppl:A10630.
30. Marzese DM, et al. (2011) The relationship between the number of aberrantly methylated regions and the methylation status of p73 and RARβ genes and prognosis in patients with breast cancer. J. Clin. Oncol. 29 Suppl:A10542.
31. Simpson N, Syed BM, Morgan DAL, Ellis IO, Cheung K. (2011) Pattern of estrogen receptor (ER)/progesterone receptor (PR)/HER2 expression in older women with primary breast cancer based on core needle biopsies and correlation with short-term clinical outcome. J. Clin. Oncol. 29 Suppl:Ae21104.
32. Basik M, et al. (2011) Measurement of Pax2, TC21, CCND1, and RFS1 as predictive biomarkers for outcomes in the NCIC CTG MA.12 trial of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer. J. Clin. Oncol. 29 Suppl:A560.
33. Giordano A, et al. (2011) Epithelial-mesenchymal transition in patients with HER2+ metastatic breast cancer. J. Clin. Oncol. 29 Suppl:A623.
34. Siegel PM, Muller WJ. (2010) Transcription factor regulatory networks in mammary epithelial development and tumorigenesis. Oncogene. 29:2753-9.
35. Casas E, et al. (2011) Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res. 71:245-54.
36. Haftchenary S, Avadisian M, Gunning PT. (2011) Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report. Anti-Cancer Drugs. 22:115-27.
37. Bodily JM, Mehta KP, Laimins LA. (2011) Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediated transcription by inhibiting binding of histone deacetylases. Cancer Res. 71:1187-95.
38. Yin L, Velazquez OC, Liu ZJ. (2010) Notch signaling: emerging molecular targets for cancer therapy. Biochem. Pharmacol. 80:690-701.
39. Konstantinopoulos PA, Papavassiliou AG. (2011) Seeing the future of cancer-associated transcription factor drug targets. JAMA. 305:2349-50.
40. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. (2007) Epigenomics in respiratory epithelium carcinogenesis: prevention and therapeutic challenges. Cancer Treat. Rev. 33:284-8.